Logo image of PEPG

PEPGEN INC (PEPG) Stock Fundamental Analysis

NASDAQ:PEPG - Nasdaq - US7133171055 - Common Stock - Currency: USD

1.59  +0.12 (+8.16%)

After market: 1.61 +0.02 (+1.26%)

Fundamental Rating

2

Taking everything into account, PEPG scores 2 out of 10 in our fundamental rating. PEPG was compared to 566 industry peers in the Biotechnology industry. While PEPG has a great health rating, there are worries on its profitability. PEPG does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year PEPG has reported negative net income.
PEPG had a negative operating cash flow in the past year.
PEPG had negative earnings in each of the past 5 years.
In the past 5 years PEPG always reported negative operating cash flow.
PEPG Yearly Net Income VS EBIT VS OCF VS FCFPEPG Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

PEPG has a Return On Assets of -59.64%. This is in the lower half of the industry: PEPG underperforms 60.07% of its industry peers.
PEPG has a Return On Equity (-75.86%) which is in line with its industry peers.
Industry RankSector Rank
ROA -59.64%
ROE -75.86%
ROIC N/A
ROA(3y)-48.79%
ROA(5y)-36.64%
ROE(3y)-62.28%
ROE(5y)-45.33%
ROIC(3y)N/A
ROIC(5y)N/A
PEPG Yearly ROA, ROE, ROICPEPG Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PEPG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PEPG Yearly Profit, Operating, Gross MarginsPEPG Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

7

2. Health

2.1 Basic Checks

The number of shares outstanding for PEPG has been increased compared to 1 year ago.
PEPG has more shares outstanding than it did 5 years ago.
PEPG has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
PEPG Yearly Shares OutstandingPEPG Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
PEPG Yearly Total Debt VS Total AssetsPEPG Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -2.91, we must say that PEPG is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PEPG (-2.91) is comparable to the rest of the industry.
There is no outstanding debt for PEPG. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.91
ROIC/WACCN/A
WACCN/A
PEPG Yearly LT Debt VS Equity VS FCFPEPG Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

PEPG has a Current Ratio of 7.41. This indicates that PEPG is financially healthy and has no problem in meeting its short term obligations.
PEPG has a Current ratio of 7.41. This is in the better half of the industry: PEPG outperforms 70.85% of its industry peers.
A Quick Ratio of 7.41 indicates that PEPG has no problem at all paying its short term obligations.
PEPG's Quick ratio of 7.41 is fine compared to the rest of the industry. PEPG outperforms 71.20% of its industry peers.
Industry RankSector Rank
Current Ratio 7.41
Quick Ratio 7.41
PEPG Yearly Current Assets VS Current LiabilitesPEPG Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 13.88% over the past year.
EPS 1Y (TTM)13.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.8%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, PEPG will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.56% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.32%
EPS Next 2Y6.44%
EPS Next 3Y9.14%
EPS Next 5Y13.56%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PEPG Yearly Revenue VS EstimatesPEPG Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 100M 200M 300M
PEPG Yearly EPS VS EstimatesPEPG Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PEPG. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PEPG. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PEPG Price Earnings VS Forward Price EarningsPEPG Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PEPG Per share dataPEPG EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.44%
EPS Next 3Y9.14%

0

5. Dividend

5.1 Amount

PEPG does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

PEPGEN INC

NASDAQ:PEPG (5/2/2025, 8:16:57 PM)

After market: 1.61 +0.02 (+1.26%)

1.59

+0.12 (+8.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24 2025-02-24/bmo
Earnings (Next)05-12 2025-05-12
Inst Owners92.28%
Inst Owner Change0%
Ins Owners0.02%
Ins Owner Change4.23%
Market Cap52.02M
Analysts83.64
Price Target12.44 (682.39%)
Short Float %8.86%
Short Ratio0.82
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.58%
Min EPS beat(2)17.71%
Max EPS beat(2)25.45%
EPS beat(4)3
Avg EPS beat(4)10.28%
Min EPS beat(4)-18.14%
Max EPS beat(4)25.45%
EPS beat(8)6
Avg EPS beat(8)8.61%
EPS beat(12)8
Avg EPS beat(12)-16.4%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.13%
EPS NY rev (1m)0%
EPS NY rev (3m)0.74%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)-2.84
EYN/A
EPS(NY)-2.72
Fwd EYN/A
FCF(TTM)-2.53
FCFYN/A
OCF(TTM)-2.52
OCFYN/A
SpS0
BVpS3.63
TBVpS3.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -59.64%
ROE -75.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.79%
ROA(5y)-36.64%
ROE(3y)-62.28%
ROE(5y)-45.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 33.02%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.41
Quick Ratio 7.41
Altman-Z -2.91
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)339.96%
Cap/Depr(5y)261.35%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.8%
EPS Next Y4.32%
EPS Next 2Y6.44%
EPS Next 3Y9.14%
EPS Next 5Y13.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.45%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.38%
OCF growth 3YN/A
OCF growth 5YN/A